Subscribe

Zhejiang Taimei Medical Technology Co., Ltd. (2576.HK)

HKD6.10 -0.06 (-0.97%)
CN HKSE Technology Software - Application
Address No.9 Building 314000
Jiaxing, CN
CEO Zhao Lu
IPO 2024-10-08
ISIN CNE100006M66

Explore sections of this company profile

Description

Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The company's core offering is TrialOS, a comprehensive digital collaboration platform that seamlessly integrates all participants throughout the drug development and research lifecycle. This ecosystem effectively links hospitals, pharmaceutical firms, external service providers, regulatory bodies, and patients, among other key industry stakeholders. Its extensive portfolio of software solutions caters to various critical aspects of clinical research and drug development. For streamlining clinical trial operations, Taimei Medical provides tools like eCooperate, which optimizes management systems and leverages big data for informed decision-making. Other related offerings include eArchives for managing master files, eCollect for electronic data capture, eCollege for training administration, eQuality for electronic audit processes, and eBalance for interactive web-based responses. Innovations such as eVisit Patient Reported Outcomes are designed to enhance patient data input and accuracy, while eTime supports project time management, and eImage facilitates medical image interpretation. Furthermore, the company supplies specialized software tailored for hospitals and Good Clinical Practice (GCP) sites. These include eTrial for managing Phase I wards, eSite and NomenCTMS for comprehensive clinical trial management at study sites, and intelligent platforms like GCP-X and Intelligent Investigator. Solutions such as eScreening assist with subject information management and deduplication, while IIT-EDC and the Investigator-Initiated Clinical Trial Management System support investigator-initiated studies and their associated data management. In the crucial domain of drug safety, the company offers robust pharmacovigilance software solutions. This includes both global and intelligent eSafety systems, alongside the SAE Manager for efficient communication and management of critical safety data during clinical trials. Complementing these, Zhejiang Taimei also develops marketing software and a variety of other digital innovation solutions.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD6.10 -0.06 (-0.97%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
589.8K
Beta
0.32
Float Shares
526.48M
Free Float %
93.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-2.23% -4.57% -2.01% -9.11% +10.86% +10.86% +29.50% -52.28% -52.28% -52.28% -52.28%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
6.10
DCF (Unlevered) 4.68 -23.3%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 0% Bullish
Rating 2025-06 Change
Strong Buy 0 0
Buy 0 0
Hold 1 0
Sell 0 0
Strong Sell 0 0
Quality scores
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • Revenue growth Software - Application: +13.0%
    -9.4%
  • EPS growth Software - Application: +28.6%
    +81.0%
  • FCF margin FCF growth · Software - Application: +45.3%
    -9.2% Q1'24: -85.6%
  • EBIT margin Software - Application: +9.4%
    -12.3% Q1'24: -89.4%
  • ROIC Software - Application: +7.5%
    -102.4% Q1'24: -785.8%
  • Share dilution Software - Application: +0.0%
    +0.0%
  • Debt / EBITDA Net debt/EBITDA · Software - Application: -1.16×
    -1.45× Q1'24: -0.15×
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.41) × ERP
WACC = 97% × Ke + 3% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Intrinsic value (base): 4.69 Current price: 6.10
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2024
actual
Dec 2025
actual
Dec 2026
1 Rev. Ana.
1 EPS Ana.
Revenue
551.16M
est: 572.64M (-3.8%)
499.28M
est: 687.14M (-27.3%)
840.70M
840.70M – 840.70M
+22.3% YoY
EBITDA
-176.73M
est: 264.23M (-166.9%)
-42.04M
est: 317.06M (-113.3%)
387.91M
387.91M – 387.91M
+22.3% YoY
EBIT
-216.68M
est: 255.35M (-184.9%)
-61.50M
est: 306.40M (-120.1%)
374.87M
374.87M – 374.87M
+22.3% YoY
Net Income
-214.61M
est: -90.17M (-138.0%)
-41.74M
est: 16.91M (-346.9%)
64.32M
64.32M – 64.32M
+280.4% YoY
SGA
382.02M
est: 223.00M (+71.3%)
196.78M
est: 267.59M (-26.5%)
327.39M
327.39M – 327.39M
+22.3% YoY
EPS
-0.39
est: -0.16 (-143.8%)
-0.07
est: 0.03 (-346.8%)
0.11
0.11 – 0.11
+280.4% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-28 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-27 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-26 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-22 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-21 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-20 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-19 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-18 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-15 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-14 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-13 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-12 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-11 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-08 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-07 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-06 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-05 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-04 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-30 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-29 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-28 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-27 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-24 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-23 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-22 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-21 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-20 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-17 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-16 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
Ownership data is not available for this company yet.

Executive team

Top executives
EBIT / Employee
-98.1K
Shares Outstanding
563.85M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Zhao Lu Executive Chairman 9M male
Dong Ma Chief Product Officer & Director 3M male
Hongwei Zhang Head of Digital Marketing Division & Executive Director 2M male
Yiming Lu Chief Technology Officer & Director 2M male
Xiaomei Ni Executive Director, Legal Director & Board secretary 2M female
Yufei Huang Executive Director & Head of the operations assurance division 2M male
Ping Yeung Poon Joint Secretary male
Yunyun Wan General Manager female
Wei Wang Chief Financial Officer male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits